CardiologyFamilial HypercholesterolaemiaLDL Cholesterol
PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function
By MedXY|May 3, 2026
In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-bas